Dan Staerk

Prof. Dan Staerk

University of Copenhagen, Department of Drug Design and Pharmacology
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2016 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
JAJohan Andersen‐Ranberg
Johan Andersen‐Ranberg
Kenneth KongstadKenneth Kongstad
Kenneth Kongstad
MNMorten Thrane Nielsen
Morten Thrane Nielsen
NJNiels Bjerg Jensen
Niels Bjerg Jensen
IPIrini Pateraki
Irini Pateraki
BHBjoern Hamberger
Bjoern Hamberger
Plant‐derived diterpenoids serve as important pharmaceuticals, food additives, and fragrances, yet their low natural abundance and high structural complexity limits their broader industrial utilization. By mimicking the modularity of diterpene biosynthesis in plants, we constructed 51 functional combinations of class I and II diterpene synthases, 41 of which are “new‐to‐nature”. Stereoselective biosynthesis of over 50 diterpene skeletons was demonstrated, including natural variants and novel enantiomeric or diastereomeric counterparts. Scalable biotechnological production for four industrially relevant targets was accomplished in engineered strains of Saccharomyces cerevisiae.

1 April 2004 in Journal of Natural Products
Verified
Journal Article
Closed access
GBGerhard Bringmann
Gerhard Bringmann
MDMichael Dreyer
Michael Dreyer
JFJohan H. Faber
Johan H. Faber
PDPetur Weihe Dalsgaard
Petur Weihe Dalsgaard
Dan StaerkDan Staerk
Dan Staerk
SCSøren Brøgger Christensen
Søren Brøgger Christensen

16 August 2002 in Journal of Natural Products
Verified
Journal Article
Closed access
Dan StaerkDan Staerk
Dan Staerk
ALAnne K. Lykkeberg
Anne K. Lykkeberg
JCJette Christensen
Jette Christensen
BBBogdan A. Budnik
Bogdan A. Budnik
FAFumiko Abe
Fumiko Abe
JJJerzy W. Jaroszewski
Jerzy W. Jaroszewski

17 October 2001 in Journal of Natural Products
Verified
Journal Article
Closed access
MSMajid Sairafianpour
Majid Sairafianpour
JCJette Christensen
Jette Christensen
Dan StaerkDan Staerk
Dan Staerk
BBBogdan A. Budnik
Bogdan A. Budnik
AKArsalan Kharazmi
Arsalan Kharazmi
JJJerzy W. Jaroszewski
Jerzy W. Jaroszewski

1 June 2016 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
BTBinh T.D. Trinh
Binh T.D. Trinh
Dan StaerkDan Staerk
Dan Staerk
AJAnna Jager
Anna Jager

14 March 2017 in eLife
Verified
Journal Article
Open access
IPIrini Pateraki
Irini Pateraki
JAJohan Andersen-Ranberg
Johan Andersen-Ranberg
NJNiels Bjerg Jensen
Niels Bjerg Jensen
SWSileshi Gizachew Wubshet
Sileshi Gizachew Wubshet
AHAllison Maree Heskes
Allison Maree Heskes
BHBjoern Hamberger
Bjoern Hamberger
Forskolin is a unique structurally complex labdane-type diterpenoid used in the treatment of glaucoma and heart failure based on its activity as a cyclic AMP booster. Commercial production of forskolin relies exclusively on extraction from its only known natural source, the plant Coleus forskohlii, in which forskolin accumulates in the root cork. Here, we report the discovery of five cytochrome P450s and two acetyltransferases which catalyze a cascade of reactions converting the forskolin precursor 13R-manoyl oxide into forskolin and a diverse array of additional labdane-type diterpenoids. A minimal set of three P450s in combination with a single acetyl transferase was identified that catalyzes the conversion of 13R-manoyl oxide into forskolin as demonstrated by transient expression in Nicotiana benthamiana. The entire pathway for forskolin production from glucose encompassing expression of nine genes was stably integrated into Saccharomyces cerevisiae and afforded forskolin titers of 40 mg/L.